Literature DB >> 21278392

A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations.

Saba Sharif1, Meena Upadhyaya, Rosalie Ferner, Elisa Majounie, Andrew Shenton, Michael Baser, Nalin Thakker, D Gareth Evans.   

Abstract

BACKGROUND: Neurofibromatosis type 1 (NF1) affects 1 in 2500 people, and 15% of these may develop an optic pathway glioma (OPG). OPGs behave differently in NF1, and, given their frequency, surveillance is important. However, this is difficult because of the additional complications these patients may have, such as learning difficulties. Management is also different given that NF1 results from loss of function of tumour suppressor gene. A genotype-phenotype correlation may help to determine who is at risk of developing these tumours, aid focused screening, and shed light on response to treatments.
METHODS: As part of a long-term follow-up study of patients with NF1 OPGs, the authors assessed genotype-phenotype correlation. Fluorescein in situ hybridisation was performed to identify large deletions, and then a full gene screen for mutations, by denaturing high-performance liquid chromatography.
RESULTS: 80 patients with NF1 OPGs were identified, and molecular analyses were performed in a subset of 29. A clustering of pathogenic changes in the 5' tertile of the gene was found. The authors combined these results with those for another two NF1 OPG cohorts and collectively found the same trend. When compared with a control population of NF1 patients without an OPG, the OR of a mutation being present in the 5' tertile was 6.05 (p=0.003) in the NF1 OPG combined cohorts.
CONCLUSION: It is possible that genotype is a significant determinant of the risk of development of OPGs in NF1.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21278392     DOI: 10.1136/jmg.2010.081760

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  38 in total

1.  Neurofibromatosis 1-associated optic pathway gliomas.

Authors:  Ben Shofty; Liat Ben Sira; Shlomi Constantini
Journal:  Childs Nerv Syst       Date:  2020-06-11       Impact factor: 1.475

2.  When and why is surgical revascularization indicated for the treatment of moyamoya syndrome in patients with RASopathies? A systematic review of the literature and a single institute experience.

Authors:  Marcello Scala; Pietro Fiaschi; Valeria Capra; Maria Luisa Garrè; Domenico Tortora; Marcello Ravegnani; Marco Pavanello
Journal:  Childs Nerv Syst       Date:  2018-05-24       Impact factor: 1.475

3.  NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1.

Authors:  Joseph A Toonen; Corina Anastasaki; Laura J Smithson; Scott M Gianino; Kairong Li; Robert A Kesterson; David H Gutmann
Journal:  Hum Mol Genet       Date:  2016-02-16       Impact factor: 6.150

4.  Elucidating the impact of neurofibromatosis-1 germline mutations on neurofibromin function and dopamine-based learning.

Authors:  Corina Anastasaki; Albert S Woo; Ludwine M Messiaen; David H Gutmann
Journal:  Hum Mol Genet       Date:  2015-03-18       Impact factor: 6.150

5.  Peri-gestational risk factors for pediatric brain tumors in Neurofibromatosis Type 1.

Authors:  Kimberly J Johnson; Nancy L Zoellner; David H Gutmann
Journal:  Cancer Epidemiol       Date:  2016-03-25       Impact factor: 2.984

Review 6.  Role of visual evoked potentials in the assessment and management of optic pathway gliomas in children.

Authors:  C Van Mierlo; W Spileers; E Legius; I Casteels; C Cassiman
Journal:  Doc Ophthalmol       Date:  2013-07-25       Impact factor: 2.379

7.  Exploring the genetic basis for clinical variation in neurofibromatosis type 1.

Authors:  David H Gutmann
Journal:  Expert Rev Neurother       Date:  2016-05-30       Impact factor: 4.618

8.  Treatment of neurofibromatosis type 1.

Authors:  Caterina Sabatini; Donatella Milani; Francesca Menni; Gianluca Tadini; Susanna Esposito
Journal:  Curr Treat Options Neurol       Date:  2015-06       Impact factor: 3.598

9.  Increased rate of missense/in-frame mutations in individuals with NF1-related pulmonary stenosis: a novel genotype-phenotype correlation.

Authors:  Shay Ben-Shachar; Shlomi Constantini; Hen Hallevi; Emma K Sach; Meena Upadhyaya; Gareth D Evans; Susan M Huson
Journal:  Eur J Hum Genet       Date:  2012-10-10       Impact factor: 4.246

10.  Temporal, spatial, and genetic constraints contribute to the patterning and penetrance of murine neurofibromatosis-1 optic glioma.

Authors:  Nicole M Brossier; Sharanya Thondapu; Olivia M Cobb; Sonika Dahiya; David H Gutmann
Journal:  Neuro Oncol       Date:  2021-04-12       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.